Chart pattern: Double Bottom (weekly)
▲ Broken out
Broke on Nov 06, 2026 · measured target $106.66 (+4%). Details →
Nov 4, 4:21 PM ET
Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, representing a 10.5% increase compared to the prior year. Driven by strong procedure volumes and robust performance across its businesses, the company raised its full-year 2026 sales growth and adjusted EPS guidance.
- Q3 sales grew 10.5% to $1.72 billion, with constant currency sales up 11.2%.
- Q3 EPS was $0.53, while adjusted EPS reached $0.80, up 19% versus the prior year.
- Full-year 2026 sales growth guidance was increased to approximately 11.5% from the previous 10% to 11% range.
- Adjusted EPS guidance for 2026 was raised to a range of $2.97 to $3.05.
Read the filing on SEC.gov ↗
Aug 28, 4:15 PM ET
Edwards Lifesciences said Donald E. Bobo, Jr., its Corporate Vice President, Strategy and Corporate Development, will retire by mid-year 2027. The company will begin searching for a successor, with the transition expected during 2027. Mr. Bobo is expected to stay on as a consultant through the end of 2027.
- Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, will retire by mid-year 2027
- A selection process for a successor begins promptly; the transition of duties is expected during 2027
- Mr. Bobo is expected to remain as a consultant through the end of 2027
Read the filing on SEC.gov ↗
Jul 23, 4:29 PM ET
Edwards Lifesciences reported second-quarter 2026 sales of $1.74 billion, up 13.6% from a year earlier, and raised its full-year 2026 sales growth guidance to 10% to 11% on a constant currency basis. GAAP diluted EPS fell to $0.42 from $0.56 because of a $188.2 million tax valuation allowance tied to California budget legislation, while adjusted EPS rose to $0.78 from $0.67 and full-year adjusted EPS guidance of $2.95 to $3.05 was reaffirmed.
- Q2 2026 net sales were $1.74 billion, up from $1.53 billion in Q2 2025; TAVR sales were $1.26 billion, up 11.3%.
- GAAP diluted EPS was $0.42 versus $0.56 a year earlier, including a $188.2 million valuation allowance against deferred tax assets.
- Full-year 2026 sales growth guidance was raised to 10% to 11% from 9% to 11%; adjusted EPS guidance of $2.95 to $3.05 was reaffirmed.
- For Q3 2026, Edwards projects total sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77.
Read the filing on SEC.gov ↗
May 8, 4:12 PM ET
At its May 7, 2026 annual meeting, Edwards Lifesciences stockholders approved an amendment to the Long-Term Stock Incentive Compensation Program that adds 7,000,000 shares, bringing the total share limit to 341,500,000. Stockholders also elected all nine director nominees and approved the advisory vote on named executive officer compensation and the auditor ratification.
- Share limit under the Long-Term Stock Program rises by 7,000,000 shares to 341,500,000 shares.
- Stockholder approval of the amended program: 456,675,201 for and 19,210,539 against.
- All nine director nominees were elected, including David T. Feinberg, MD, and Bernard J. Zovighian.
- Advisory executive pay proposal passed with 424,961,639 for and 50,924,101 against.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.